Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference
Sight Sciences, a growth-stage medical device company (Nasdaq: SGHT), will participate in the Morgan Stanley Global Healthcare Conference on September 9, 2021, at 9:30 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sight Sciences, a growth-stage medical device company (Nasdaq: SGHT), will participate in the Morgan Stanley Global Healthcare Conference on September 9, 2021, at 9:30 am ET. The event will be accessible via a live and archived webcast on their website. Founded in 2011, Sight Sciences focuses on addressing major eye diseases with innovative products like the OMNI® Surgical System and the TearCare® System. For more details, visit their official website.
Details
News Market Reaction – SGHT
The recorded move for SGHT in the trading session of this news was +1.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced plans to participate in the upcoming virtual Morgan Stanley Global Healthcare Conference.
Sight Sciences’ management is scheduled to present Thursday, September 9, 2021 at 9:30am ET. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.sightsciences.com/ .
About Sight Sciences
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world’s most prevalent eye diseases. The company currently markets two products, the OMNI® Surgical System and the TearCare® System. For more information, visit www.sightsciences.com.
Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.